Quick Answer
Sarepta Therapeutics, Inc. reported R&D Expense of $401.84 million for fiscal year 2018.
Sarepta Therapeutics, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2018 | $401.84M | +141.0% |
| 2017 | $166.71M | -11.5% |
| 2016 | $188.27M | +28.6% |
| 2015 | $146.39M | +55.4% |
| 2014 | $94.23M | +29.2% |
| 2013 | $72.91M | +39.1% |
| 2012 | $52.40M | -21.6% |
| 2011 | $66.86M | +85.9% |
| 2010 | $35.97M | +47.5% |
| 2009 | $24.40M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| June 30, 2019 | $113.27M | -7.8% | +25.1% |
| March 31, 2019 | $90.55M | +96.0% | +4.6% |
| September 30, 2018 | $86.58M | +152.9% | -29.5% |
| June 30, 2018 | $122.85M | +108.5% | +165.9% |
| March 31, 2018 | $46.20M | +58.7% | +34.9% |
| September 30, 2017 | $34.24M | -0.3% | -41.9% |
| June 30, 2017 | $58.91M | +32.8% | +102.3% |
| March 31, 2017 | $29.12M | -25.0% | -15.2% |
- Sarepta Therapeutics, Inc. showed an increase of +141.0% in R&D Expense compared to the prior fiscal year.
- Over the 2009–2018 period, Sarepta Therapeutics, Inc.’s r&d expense has grown by 1547.2% (from $24.40 million to $401.84 million).
- The most recent figure is from Sarepta Therapeutics, Inc.’s fiscal year 2018 report (Form 10-K), filed with the SEC on February 28, 2019.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: